Daily Sepsis Research Analysis
Three impactful studies advance sepsis care this week: a post hoc analysis of the EXIT-SEP RCT shows phenotype-specific benefits of Xuebijing injection, a comprehensive review outlines rapid direct-from-blood diagnostics for bloodstream infection, and a meta-analysis suggests ulinastatin plus continuous blood purification reduces inflammation and mortality despite publication bias. Together, they highlight precision phenotyping, faster diagnostics, and adjunctive immunomodulation.
Summary
Three impactful studies advance sepsis care this week: a post hoc analysis of the EXIT-SEP RCT shows phenotype-specific benefits of Xuebijing injection, a comprehensive review outlines rapid direct-from-blood diagnostics for bloodstream infection, and a meta-analysis suggests ulinastatin plus continuous blood purification reduces inflammation and mortality despite publication bias. Together, they highlight precision phenotyping, faster diagnostics, and adjunctive immunomodulation.
Research Themes
- Precision phenotyping and heterogeneity of treatment effects in sepsis
- Rapid direct-from-blood molecular diagnostics for bloodstream infection
- Adjunctive immunomodulatory strategies and extracorporeal therapies
Selected Articles
1. Treatment effects of Xuebijing injection in patients with sepsis by clinical phenotype: a post hoc analysis of the EXIT-SEP trial.
This post hoc analysis of 1,760 EXIT-SEP participants replicated four sepsis phenotypes and found that Xuebijing was associated with reduced 28-day mortality in γ and δ phenotypes, with more ventilator- and ICU-free days in δ. A compact classifier accurately predicted phenotypes (AUROCs 0.893–0.945), supporting phenotype-guided therapy, though interaction tests were not significant.
Impact: It advances precision medicine by linking sepsis phenotypes to differential treatment response and provides a validated classifier for bedside stratification.
Clinical Implications: Clinicians could consider prioritizing Xuebijing for patients clustered into γ (respiratory dysfunction) or δ (acidosis, coagulopathy, shock) phenotypes while awaiting confirmatory trials, using phenotype classifiers to target therapy.
Key Findings
- Four SENECA sepsis phenotypes (α, β, γ, δ) were replicated in 1,760 patients.
- XBJ was associated with lower 28-day mortality in γ (p=0.003) and δ (p=0.033) phenotypes.
- In δ phenotype, XBJ increased ventilator-free and ICU-free days (interaction p<0.001).
- A parsimonious classifier predicted phenotypes with AUROCs 0.893–0.945.
Methodological Strengths
- Large multicenter dataset from an RCT with standardized treatment arms
- Replication of externally proposed phenotypes and development of an accurate classifier
Limitations
- Post hoc analysis; treatment-by-phenotype interaction not statistically significant
- Generalizability outside Chinese ICUs and to non-XBJ settings remains uncertain
Future Directions: Prospective, phenotype-stratified randomized trials to confirm benefit in γ and δ clusters and to integrate classifier-guided enrollment.
BACKGROUND: Xuebijing injection (XBJ) could improve the outcomes of sepsis patients. However, sepsis is a heterogeneous syndrome, and it remains unclear which patients benefit the most. We aimed to identify the sepsis phenotypes most likely to benefit from XBJ treatment. METHODS: This post hoc analysis of the EXIT-SEP trial included sepsis patients from 45 intensive care units (ICUs) in China between October 2017 and June 2019. The XBJ group received 100 mL of XBJ every 12 h for 5 days, while the placebo group was given a volume-matched saline. Consensus FINDINGS: Among 1760 patients (878 in the XBJ group and 882 in the placebo group), four sepsis phenotypes (α: 28.2%, β: 24.0%, γ: 28.9%, and δ: 18.9%) were replicated based on the SENECA classification. Phenotype α had the lowest 28-day mortality. Phenotype β was associated with older age, chronic illness, and renal dysfunction. Phenotype γ was characterized by respiratory dysfunction. Phenotype δ was associated with acidosis, elevated alanine transaminase, coagulation dysfunction, shock, and the highest 28-day mortality (32.5%). Compared with placebo, XBJ treatment was associated with lower 28-day mortality in patients with phenotype γ (p = 0.003) and δ (p = 0.033), while the treatment-by-phenotype interaction was not statistically significant. Additionally, patients with phenotype δ who received XBJ had more ventilator-free days and ICU-free days than those with phenotype α, with p for interaction < 0.001 for both outcomes. Finally, a parsimonious classifier model demonstrated good accuracy in phenotype prediction, with AUROCs of 0.937 (95% CI: 0.916-0.957) for α, 0.893 (0.861-0.924) for β, 0.945 (0.927-0.964) for γ, and 0.900 (0.866-0.935) for δ in the internal validation cohort. INTERPRETATION: We replicated four sepsis phenotypes in the EXIT-SEP cohort, with patterns similar to previously established phenotypes. XBJ treatment was associated with lower 28-day mortality in patients with phenotypes γ and δ, but these findings require further validation. FUNDING: This study was funded by the National Natural Science Foundation of China; Noncommunicable Chronic Diseases-National Science and Technology Major Project; Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Construction Funds; Nanjing Technology Development Program; The Pilot Project of the Flagship Hospital of Integrated Traditional Chinese and Western Medicines in Zhongda Hospital affiliated to Southeast University.
2. Direct Testing of Blood Samples to Diagnose Bloodstream Infections.
This review synthesizes direct-from-blood diagnostic technologies for bloodstream infection, including Raman spectroscopy, mass spectrometry, NAATs (CRISPR/Cas, ddPCR), T2MR, biosensors, and NGS. These approaches can rapidly identify pathogens and resistance markers, potentially transforming BSI diagnosis by shortening time-to-targeted therapy.
Impact: By mapping the technological landscape and trade-offs, it guides translation of rapid diagnostics into clinical workflows and antimicrobial stewardship.
Clinical Implications: Hospitals can evaluate and integrate rapid direct-from-blood platforms to shorten time to effective therapy, improve source control decisions, and enhance stewardship, particularly for high-risk sepsis and neutropenic patients.
Key Findings
- Direct-from-blood methods (Raman, MS, NAATs including CRISPR/Cas and ddPCR, T2MR, biosensors, NGS) can rapidly detect pathogens and resistance markers.
- These technologies reduce reliance on time-consuming blood culture and may shorten time-to-targeted therapy.
- The review outlines principles, advantages, and limitations to inform selection and implementation.
Methodological Strengths
- Comprehensive and comparative synthesis of multiple cutting-edge diagnostic modalities
- Focus on both pathogen identification and antimicrobial resistance detection
Limitations
- Narrative technology review without quantitative meta-analysis of diagnostic accuracy
- Clinical outcome impact, cost-effectiveness, and implementation barriers are not systematically evaluated
Future Directions: Head-to-head diagnostic accuracy studies with clinical impact endpoints, cost-effectiveness analyses, and integration into sepsis care pathways.
Bloodstream infection (BSI) is a critical condition with extremely high mortality. Rapid and accurate diagnosis is crucial for effective treatment. The traditional blood culture (BC) method has issues, such as long testing times and limited sensitivity, making it challenging to meet the need for timely diagnosis. To address this problem, various molecular biology methods for directly detecting blood samples (whole blood, plasma, serum, and positive BC samples) have emerged. These include Raman spectroscopy, mass spectrometry, nucleic acid amplification, and hybridization techniques (such as the CRISPR/Cas system, digital droplet PCR (ddPCR), and T2 magnetic resonance (T2MR)), biosensors, and next-generation sequencing (NGS). These methods can quickly identify pathogens and their drug-resistant markers, significantly reducing diagnostic delays and helping to provide earlier targeted treatment. This article systematically analyzes the principles, advantages, and disadvantages of these advanced techniques, explores their value in revolutionizing the BSI diagnostic model, and looks ahead to future development directions, providing a reference for research and clinical applications in this field.
3. Immunomodulatory effects of ulinastatin combined with continuous blood purification in sepsis: a systematic review and meta-analysis.
Across 34 studies (28 RCTs, 6 retrospective), ulinastatin plus continuous blood purification significantly reduced inflammatory cytokines and was associated with lower mortality (OR 0.30). However, publication bias was detected, underscoring the need for high-quality confirmatory trials.
Impact: Suggests an adjunctive therapy that may improve survival in sepsis while providing a mechanistic anti-inflammatory rationale.
Clinical Implications: In centers with CBP capability, clinicians may consider ulinastatin as an adjunct for hyperinflammatory sepsis while carefully weighing evidence quality and monitoring for future definitive RCTs.
Key Findings
- Meta-analysis of 34 studies (28 RCTs, 6 retrospective) in sepsis.
- Significant reductions in CRP, IL-1β, IL-6, IL-8, IL-10, PCT, and TNF-α with ulinastatin + CBP.
- Lower mortality with adjunct therapy (OR 0.30, 95% CI 0.22–0.42).
- Egger's test indicated significant publication bias (p = 0.002).
Methodological Strengths
- Inclusion of numerous RCTs and clinically meaningful endpoints (mortality)
- Consistent direction of effect across multiple inflammatory biomarkers
Limitations
- Significant publication bias and potential heterogeneity across included studies
- Variability in CBP protocols, patient selection, and ulinastatin dosing
Future Directions: Rigorous, multicenter, placebo-controlled RCTs with standardized CBP protocols to confirm mortality benefit and define target populations.
BACKGROUND: Sepsis involves a dysregulated immune response to infection, causing inflammation and organ dysfunction. This systematic review and meta-analysis evaluated the immunomodulatory effects of ulinastatin combined with continuous blood purification (CBP) in sepsis. METHODS: This study involved a literature search, data extraction, quality assessment, and meta-analysis to evaluate the effects of ulinastatin combined with CBP. A total of 34 studies, including 28 randomized controlled trials (RCTs) and 6 retrospective studies involving patients with sepsis, were included. RESULTS: The pooled results demonstrated significant reductions in inflammatory markers including CRP (SMD: 2.210, 95% CI: 2.760 to -1.661, P < 0.0001), IL-1β (SMD: 1.536, 95% CI: 1.773 to -1.299, P < 0.0001), IL-6 (SMD: 2.679, 95% CI: 3.271 to -2.086, P < 0.0001), IL-8 (SMD: 2.959, 95% CI: 4.582 to -1.337, P < 0.0001), IL-10 (SMD: 4.449, 95% CI: 7.216 to -1.682, P = 0.002), PCT (SMD: 3.787, 95% CI: 4.597 to -2.977, P < 0.0001), TNF-α (SMD: 2.734, 95% CI: 3.480 to -1.987, P < 0.0001), and mortality (OR: 0.30, 95% CI: 0.22 to 0.42, P < 0.0001) in ulinastatin group compared with control group. Egger's test indicated significant publication bias (P = 0.002). CONCLUSION: Ulinastatin combined with CBP significantly reduces inflammatory markers and mortality in sepsis patients, suggesting its potential benefit in managing sepsis-related inflammation. Further studies are needed to confirm these findings.